Related Experiment Videos
Coronary artery stenting in cardiac allograft vascular disease
B Heublein1, K Pethig, C Maass
1Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.
Insights
Percutaneous transluminal coronary angioplasty and coronary stenting improved luminal dimensions in heart transplant patients with cardiac allograft vascular disease. Primary stenting is a promising option, though long-term outcomes require further study.
Area of Science:
- Cardiology
- Transplantation immunology
- Interventional cardiology
Background:
- Cardiac allograft vascular disease (CAVD) involves myointimal hyperplasia and vascular remodeling after heart transplantation.
- Catheter-based interventions are used for selected CAVD patients.
- This study evaluates percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting in CAVD.
Purpose of the Study:
- To document the experience and outcomes of PTCA and coronary stenting in patients with CAVD.
- To assess the efficacy of these interventions in improving luminal dimensions and clinical outcomes.
- To evaluate the incidence of restenosis after stenting in CAVD.
Main Methods:
- Retrospective analysis of 27 patients undergoing 48 procedures (PTCA and stenting) 5.7 years post-transplant.
- Angiography and intravascular ultrasound were used for early and intermediate result assessment.
- Patients received aspirin and ticlopidine post-procedure.
Main Results:
- PTCA provided mild luminal gain (lumen area: 3.17 to 3.70 mm²; minimal lumen diameter: 1.84 to 2.04 mm).
- Coronary stenting significantly improved luminal gain (lumen area: 3.70 to 5.86 mm²; minimal lumen diameter: 2.04 to 2.53 mm).
- Twenty-five percent restenosis was observed at 6 months in stented vessels; no stent thrombosis or bleeding occurred.
Conclusions:
- Primary stenting is a viable option for eligible CAVD lesions, offering improved luminal dimensions.
- Aspirin and ticlopidine stabilized results and prevented complications.
- Further research is needed on stent application techniques and designs for long-term survival in CAVD.
Abstract:
Cardiac allograft vascular disease is characterized by diffuse and multifocal heterogeneous myointimal hyperplasia with or without vascular remodeling. Catheter-based interventions are indicated in selected patients. This study documents our experience with percutaneous transluminal coronary angioplasty and coronary stents (n = 48) in a group of 27 patients 5.7 +/- 2.9 years after heart transplantation. Early and intermediate results were controlled by angiography and intravascular ultrasound. Conventional percutaneous transluminal coronary angioplasty resulted in a mild and mostly inadequate gain in luminal dimensions (lumen area: 3.17 +/- 0.92 mm2 to 3.70 +/- 1.21 mm2; minimal lumen diameter: 1.84 +/- 0.23 mm to 2.04 +/- 0.36 mm). Coronary stenting led to a further improvement of luminal gain (lumen area: 3.70 +/- 1.21 mm2 to 5.86 +/- 1.76 mm2; minimal lumen diameter: 2.04 +/- 0.36 mm to 2.53 +/- 0.38 mm). These results were stabilized by application of aspirin and ticlopidine only. There were no stent thromboses or bleeding complications, and early hospital discharge of the patients was possible. At follow-up (mean follow-up period 7.72 +/- 5.45 months (range 0.50 to 23.13 months) all patients were clinically event free. In six of 24 stented vessels (25%) in 16 patients, significant restenosis (>50%) was found by intravascular ultrasound (n = 20) or by angiography (n = 4) 6 months after stent placement. We conclude that in eligible cardiac allograft vascular disease lesions primary stenting may be the method of choice. However, further evaluation of the modalities of stent application and different stent designs with respect to long-term survival is necessary.